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Accumulation of the DNA/RNA binding protein fused in sarcoma as cytoplasmic inclusions in neurons and glial cells is the
pathological hallmark of all patients with amyotrophic lateral sclerosis with mutations in FUS as well as in several subtypes
of frontotemporal lobar degeneration, which are not associated with FUS mutations. The mechanisms leading to inclusion
formation and fused in sarcoma-associated neurodegeneration are only poorly understood. Because fused in sarcoma belongs
to a family of proteins known as FET, which also includes Ewing’s sarcoma and TATA-binding protein-associated factor
15, we investigated the potential involvement of these other FET protein family members in the pathogenesis of fused in
sarcoma proteinopathies. Immunohistochemical analysis of FET proteins revealed a striking difference among the various con-
ditions, with pathology in amyotrophic lateral sclerosis with FUS mutations being labelled exclusively for fused in sarcoma,
whereas fused in sarcoma-positive inclusions in subtypes of frontotemporal lobar degeneration also consistently immunostained
for TATA-binding protein-associated factor 15 and variably for Ewing’s sarcoma. Immunoblot analysis of proteins extracted from
post-mortem tissue of frontotemporal lobar degeneration with fused in sarcoma pathology demonstrated a relative shift of all
FET proteins towards insoluble protein fractions, while genetic analysis of the TATA-binding protein-associated factor 15
and Ewing’s sarcoma gene did not identify any pathogenic variants. Cell culture experiments replicated the findings of amyo-
trophic lateral sclerosis with FUS mutations by confirming the absence of TATA-binding protein-associated factor 15 and
Ewing’s sarcoma alterations upon expression of mutant fused in sarcoma. In contrast, all endogenous FET proteins were
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recruited into cytoplasmic stress granules upon general inhibition of Transportin-mediated nuclear import, mimicking the
findings in frontotemporal lobar degeneration with fused in sarcoma pathology. These results allow a separation of fused in
sarcoma proteinopathies caused by FUS mutations from those without a known genetic cause based on neuropathological
features. More importantly, our data imply different pathological processes underlying inclusion formation and cell death
between both conditions; the pathogenesis in amyotrophic lateral sclerosis with FUS mutations appears to be more restricted
to dysfunction of fused in sarcoma, while a more global and complex dysregulation of all FET proteins is involved in the
subtypes of frontotemporal lobar degeneration with fused in sarcoma pathology.
Keywords: FUS; TAF15; EWS; amyotrophic lateral sclerosis; frontotemporal dementia
Abbreviations: ALS = amyotrophic lateral sclerosis; BIBD = basophilic inclusion body disease; EWS = Ewing’s sarcoma protein;
FUS = fused in sarcoma; FTLD = frontotemporal lobar degeneration; FTLD-U = frontotemporal lobar degeneration with
ubiquitin-positive inclusions; NIFID = neuronal intermediate filament inclusion body disease; TAF15 = TATA-binding
protein-associated factor 15; TDP-43 = TAR-DNA binding protein 43 kDa
Introduction
The identification of the DNA/RNA binding protein TAR-DNA
binding protein 43 kDa (TDP-43) as the disease protein in most
forms of amyotrophic lateral sclerosis (ALS) and in the most
common form of frontotemporal lobar degeneration (FTLD), con-
firmed that these two neurodegenerative conditions belong to a
clinicopathological spectrum of diseases and initiated the concept
of RNA dysmetabolism as a crucial event in disease pathogenesis
(Neumann et al., 2006; Mackenzie et al., 2010a). This idea was
corroborated with the subsequent discovery of another DNA/RNA
binding protein fused in sarcoma (FUS), as the pathological protein
in many remaining TDP-43-negative cases with ALS and FTLD.
Briefly, the finding of mutations in the FUS gene as cause of
familial ALS (Kwiatkowski et al., 2009; Vance et al., 2009) was
rapidly confirmed in genetic screenings of large ALS cohorts
throughout the world and were found to account for 3% of
familial ALS and 1% of sporadic ALS (Mackenzie et al.,
2010a). The majority of FUS mutations cluster in the C-terminus
of the protein that encodes for a non-classical nuclear localization
sequence (Lee et al., 2006; Dormann et al., 2010). FUS mutations
have been shown to disrupt this motif, resulting in impaired
Transportin-mediated nuclear import of FUS and increased con-
centrations of cytoplasmic FUS (Dormann et al., 2010; Ito et al.,
2011; Kino et al., 2011). In line with the idea that altered nuclear
import is a key event in disease pathogenesis, the neuropathology
associated with ALS with FUS mutations (ALS-FUS) is character-
ized by abnormal cytoplasmic neuronal and glial inclusions that are
immunoreactive for FUS (Kwiatkowski et al., 2009; Vance et al.,
2009; Blair et al., 2010; Groen et al., 2010; Hewitt et al., 2010;
Rademakers et al., 2010; Mackenzie et al., 2011b).
Subsequently, FUS was studied in other neurodegenerative dis-
eases and identified as a component of the inclusions in several
subtypes of FTLD, now subsumed as FTLD-FUS (Mackenzie et al.,
2010b). This group includes cases initially designated as atypical
FTLD with ubiquitin-positive inclusions (FTLD-U) (Neumann et al.,
2009b), neuronal intermediate filament inclusion disease (NIFID)
(Neumann et al., 2009a) and basophilic inclusion body disease
(BIBD) (Munoz et al., 2009). In contrast to cases presenting
with pure ALS, which are almost always associated with mutations
in FUS, no genetic alterations of FUS have been reported to date
for cases within the FTLD-FUS group (Neumann et al., 2009a, b;
Rohrer et al., 2010; Urwin et al., 2010; Snowden et al., 2011).
Thus, the mechanisms underlying FUS accumulation in FTLD-FUS
as well as an explanation for the different patterns of FUS path-
ology in the distinct FTLD-FUS subtypes awaits further clarification
(Mackenzie et al., 2011a).
FUS is a multifunctional DNA/RNA binding protein and belongs
to the FET family of proteins that also includes Ewing’s sarcoma
protein (EWS), TATA-binding protein-associated factor 15 (TAF15)
and the Drosophila orthologue Cabeza (Law et al., 2006; Kovar
2011). The FET proteins were initially discovered as components of
fusion oncogenes that cause human cancers. Their normal func-
tion is predicted to include roles in RNA transcription, processing,
transport, microRNA processing and DNA repair (Law et al., 2006;
Tan and Manley, 2009; Kovar, 2011). In most cell types, all of the
FET proteins are predominantly localized to the nucleus, but they
are able to continuously shuttle between the nucleus and cyto-
plasm (Zinszner et al., 1997; Zakaryan and Gehring 2006; Jobert
et al., 2009). Protein-interaction studies have revealed that FET
proteins are able to interact with each other, suggesting that they
may form protein complexes (Pahlich et al., 2008; Kovar, 2011).
This raises the possibility that alterations of TAF15 and EWS might
also be involved in the pathogenesis of FUS-opathies.
In order to address this hypothesis we performed detailed
immunohistochemical, biochemical and genetic analyses of
TAF15 and EWS in a range of cases with FTLD-FUS and ALS-
FUS that covers the complete spectrum of FUS-opathies. Our
data revealed striking differences in FET protein alterations
between ALS-FUS and FTLD-FUS, thereby strongly suggesting
different disease mechanisms underlying these conditions.
Materials and methods
Case selection
Cases with FUS pathology, including atypical FTLD-U (n = 15), BIBD
(n = 7), NIFID (n = 4) and ALS-FUS (n = 6), were selected from previ-
ous studies (Munoz et al., 2009; Neumann et al., 2009a, b; Mackenzie
et al., 2011a, b). Detailed clinical and pathological description of each
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of the FTLD-FUS and ALS-FUS cases has been published previously
and is summarized in Supplementary Table 1.
Neurological control cases for immunohistochemistry included FTLD
with TDP-43 pathology [(n = 17); including sporadic subtype 1 (n = 3),
subtype 2 (n = 2), subtype 3 (n = 6), according to Mackenzie et al.
2006, familial with GRN mutations (n = 2), familial with VCP muta-
tions (n = 2) and familial linked to chromosome 9p (n = 2)], FTLD with
tau pathology (n = 8; including two each of Pick’s disease, progressive
supranuclear palsy, corticobasal degeneration and argyrophilic grain
disease), FTLD with CHMP2B mutations (n = 2), sporadic ALS with
TDP-43 pathology (n = 8), familial ALS with SOD1 mutations (n = 2),
Alzheimer’s disease (n = 4), Lewy body disease (n = 4), multiple system
atrophy (n = 2), Huntington’s disease (n = 2), spinocerebellar ataxia
(n = 3) and neuronal intranuclear inclusion body disease (n = 1).
Normal control tissue (n = 4) was from elderly patients with no history
of neurological disease.
Antibodies
A number of commercially available anti-TAF15 and anti-EWS antibo-
dies were tested by immunohistochemistry on formalin-fixed
paraffin-embedded brain tissue and by immunoblot. Results are sum-
marized in Supplementary Table 2. Three TAF15 antibodies revealed
physiological staining in tissue sections. The polyclonal antibody
TAF15-IHC-00094-1 (Bethyl) was used for staining of all cases and
for immunofluorescence. TAF15-309A and 308A (Bethyl) were used
for confirmation in selected sections and for immunoblots;
TAF15-308A was used in cell culture experiments. For EWS, four anti-
bodies revealed physiological staining in tissue sections. The monoclo-
nal antibody EWS-G5 (Santa Cruz) was used for staining of all cases,
immunofluorescence, immunoblotting and cell culture experiments.
Selected sections were stained with EWS-IHC-00086 (Bethyl),
EWS-3319-1 and EWS-3320-1 (Epitomics) for confirmation. Given
the homology of FET proteins, possible cross-reactivity of the TAF15
and EWS antibodies with FUS was excluded by immunoblot analysis
(Supplementary Fig. 1).
Other primary antibodies employed included polyclonal anti-FUS
HPA008784 (Sigma-Aldrich, 1 : 2000), FUS-302A (Bethyl, 1 : 10 000),
monoclonal anti-FUS (ProteintechGroup, 1 : 1000), monoclonal
anti--internexin (Zymed, 1 : 500), monoclonal anti-haemagglutinin
(Sigma, 1 : 500), and polyclonal anti-haemagglutinin (Sigma, 1 : 200).
Immunohistochemistry and
immunofluorescence
Immunohistochemistry was performed on 5-mm thick paraffin sections
using the Ventana BenchMark XT automated staining system (Ventana)
and developed with aminoethylcarbizole or using the NovoLinkTM
Polymer Detection Kit and developed with 3,30-diaminobenzidine.
Microwave antigen retrieval was performed for all stainings.
FUS, TAF15 and EWS pathology was evaluated using a semi-
quantitative grading system, similar to that used in previous studies
in which the pathological lesions are scored as absent (), rare ( + ),
occasional ( + + ), common ( + + + ) or numerous ( + + + + ). A grad-
ing of ‘rare’ indicates that extensive survey of the tissue section is
required for identification. ‘Occasional’ means that the lesions are
easy to find but not present in every microscopic field. The pathology
is considered ‘common’ when at least one example is present in most
high-power fields. When many lesions are present in every high-power
field, then the lesions are considered to be ‘numerous’.
Double-label immunofluorescence was performed on selected cases
for FUS and TAF15 or EWS, and -internexin and TAF15 or EWS.
The secondary antibodies were Alexa Fluor 594 and Alexa Fluor 488
conjugated anti-mouse and anti-rabbit IgG (Invitrogen, 1 : 500).
40-6-diamidino-2-phenylindol was used for nuclear counterstaining.
Immunofluorescence images of brain sections were obtained by
wide-field fluorescence microscopy (BX61 Olympus with digital
camera F-view, Olympus).
Biochemical analysis
Fresh-frozen post-mortem frontal grey matter from atypical FTLD-U
(n = 5), BIBD (n = 1), NIFID (n = 1), FTLD with TDP-43 pathology
(n = 5), Alzheimer’s disease (n = 2) and normal controls (n = 4) was
used for the sequential extraction of proteins with buffers of increasing
stringency, using a protocol described previously (Neumann et al.,
2009b). Briefly, grey matter was extracted at 2 ml/g (v/w) by repeated
homogenization and centrifugation steps (120 000 g, 30 min, 4C) with
high-salt buffer (50 mM Tris–HCl, 750 mM NaCl, 10 mM NaF, 5 mM
EDTA, pH 7.4), 1% Triton-X 100 in high-salt buffer, radioimmunopre-
cipitation assay buffer (50 mM Tris–HCl, 150 mM NaCl, 5 mM EDTA,
1% NP-40, 0.5 % sodium deoxycholate, 0.1% sodium dodecyl sul-
phate) and 2% sodium dodecyl sulphate buffer. To prevent carry over,
each extraction step was performed twice. Supernatants from the first
extraction steps were analysed while supernatants from the wash steps
were discarded. The 2% sodium dodecyl sulphate insoluble pellet was
extracted in 70% formic acid at 0.5 ml/g (v/w), evaporated in a
SpeedVac system. The dried pellet was resuspended in sample buffer
and the pH adjusted with NaOH. Protease inhibitors were added to all
buffers prior to use. For immunoblot analysis, fractions were resolved
by 7.5% sodium dodecyl sulphate–polyacrylamide gel electrophoresis
and transferred to polyvinylidene difluoride membranes (Millipore).
Membranes were blocked with Tris-buffered saline containing 3%
powdered milk and probed with anti-FUS, anti-TAF-15 or anti-EWS
antibodies. Primary antibodies were detected with horseradish
peroxidase-conjugated anti-rabbit or anti-mouse IgG (Jackson
ImmunoResearch), signals were visualized by a chemiluminescent re-
action (Pierce) and the Chemiluminescence Imager Stella 3200
(Raytest). Quantification of band intensities was performed with
AIDA software. The Mann–Whitney U-test was used for statistical
analysis of insoluble/soluble ratios with significance level set as
P5 0.05.
Cell culture experiments
HeLa cells were cultured in Dulbecco’s modified Eagle’s medium with
Glutamax (Invitrogen) supplemented with 10% (v/v) foetal calf serum
(Invitrogen) and penicillin/streptomycin. Transfection of HeLa cells was
carried out with Fugene 6 (Roche) or Lipofectamine 2000 (Invitrogen)
according to the manufacturer’s instructions. Expression vectors with
haemagglutinin-tagged human FUS with the p.P525L mutation and
with the Transportin-specific inhibitor peptide M9M fused to green
fluorescent protein were generated as described previously
(Dormann et al., 2010). In some experiments, cells were subjected
to heat shock (1 h at 44C) 24 h after transfection. For immunofluor-
escence, HeLa cells were fixed for 15 min in 4% paraformaldehyde in
phosphate-buffered saline, permeabilized for 5 min in 0.2% Triton
X-100 with 50 mM NH4Cl and subsequently blocked for 20–30 min
in 5% goat serum. Cells were stained with the indicated primary
and secondary antibodies, diluted in blocking buffer for 30 min.
Alexa Fluor 488, 555 and 647 conjugated goat anti-mouse and goat
anti-rabbit IgGs were used as secondary antibodies. To visualize nuclei,
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cells were stained with TO-PRO-3 iodide (Invitrogen) for 15 min.
Confocal images were obtained with an inverted laser scanning con-
focal microscope (Zeiss Axiovert 200M).
Genetic analysis
DNA was available from six atypical FTLD-U, one NIFID and one BIBD
case. EWS breakpoint region 1 (EWSR1) exons 1–18 and TAF15 exons
1–16 were polymerase chain reaction amplified using primers designed
to flanking intronic sequences using Qiagen products (Qiagen).
Polymerase chain reaction conditions and primer sequences available
on request. Polymerase chain reaction products were purified using the
Ampure system (Agencourt Bioscience Corporation) and sequenced
using Big Dye terminator V.3.1 products (Applied Biosystems).
Sequencing products were purified using the CleanSEQ method
(Agencourt) and analysed on an ABI 3730 DNA analyser (Applied
Biosystems). Sequence analysis was performed using Sequencher
software (Gene Codes).
Results
Detailed clinical and pathological descriptions of each of the cases
with FTLD-FUS and ALS-FUS have been published previously and
are summarized in Supplementary Table 1. TAF15 and EWS
pathology was evaluated in neuroanatomical regions previously
shown to be most affected by FUS pathology in each condition
and results are summarized in Table 1.
TAF15 and EWS pathology is present
in all subtypes of frontotemporal
lobar degeneration with FUS pathology
Immunohistochemistry for TAF15 revealed robust physiological
staining of neuronal nuclei and weaker and more variable staining
of glial nuclei in all cases and controls (Fig. 1A). All subtypes of
FTLD-FUS showed strong TAF15 immunoreactivity in neuronal
and glial inclusions that were of similar morphology, number
and anatomical distribution as demonstrated with FUS antibodies
(Fig. 1 and Table 1). Specifically, atypical FTLD-U cases showed
TAF15-positive round neuronal cytoplasmic inclusions in hippo-
campus, neocortex and lower motor neurons, as well as vermiform
or round neuronal intranuclear inclusions predominantly in the
dentate gyrus (Fig. 1B–E). NIFID and BIBD cases were found to
have numerous round or tangle-like inclusions throughout cortical,
subcortical, brainstem and spinal cord regions (Fig. 1F–H). In add-
ition to neuronal inclusions, all subtypes of FTLD-FUS revealed at
least some TAF15-positive dystrophic neurites and glial cytoplas-
mic inclusions (Fig. 1I, J) that were more numerous in NIFID and
BIBD than in atypical FTLD-U. Notably, most inclusion bearing
cells in FTLD-FUS showed a striking reduction of the physiological
nuclear staining for TAF15 (Fig. 1B and C). Similar results were
observed using TAF15 antibodies recognizing different epitopes,
including the mid-region and C-terminus.
Double-label immunofluorescence confirmed co-localization
of FUS and TAF15 in almost all inclusions in FTLD-FUS cases
(Fig. 2). There was a tendency for intranuclear inclusions in atyp-
ical FTLD-U and NIFID to be more strongly labelled for FUS
compared with TAF15 and they were rarely found to be only
FUS positive (Fig. 2B). In NIFID cases, TAF15 and -internexin
labelled discrete inclusions in the same neurons (Supplementary
Fig. 2A), a finding similar to our previous results for FUS and
-internexin (Neumann et al., 2009a).
Antibodies against EWS revealed nuclear and diffuse cytoplas-
mic staining of neuronal and glial cells as the normal physiological
staining pattern (Fig. 3A). However, EWS staining was more vari-
able among cases compared with TAF15 with some sections com-
pletely lacking physiological staining while others revealed strong
background staining making the scoring of EWS pathology in
some cases more uncertain. Nevertheless, all subtypes of
FTLD-FUS revealed at least some EWS-positive inclusions (Fig. 3
and Table 1) and similar results were obtained with four EWS
antibodies recognizing different epitopes at the N-terminal and
mid-region. Importantly, notable differences were observed be-
tween the distinct FTLD-FUS subtypes. In atypical FTLD-U,
EWS-positive neuronal cytoplasmic and intranuclear inclusions
were less numerous than those labelled with FUS, being rare to
moderate in neocortical regions and lower motor neurons
(Fig. 3B–D and G) and the staining intensity tended to be rather
weak. In contrast, inclusions in NIFID and BIBD revealed a much
more robust EWS staining intensity and the frequency of path-
ology in cortical, subcortical, brainstem and spinal cord regions
was comparable with that seen with FUS (Fig. 3E, F and H).
Due to the variability in staining intensity among cases, analysis
of the normal physiological staining pattern of EWS was more
difficult to assess; however, nuclear EWS staining was retained
in at least some inclusion bearing cells.
Double-label immunofluorescence for EWS and FUS confirmed
that in atypical FTLD-U only a subset of FUS-positive inclusions
also labelled for EWS (Fig. 4A), while most FUS pathology in
NIFID and BIBD revealed clear EWS co-localization (Fig. 4B–E).
EWS and -internexin labelled discrete inclusions in the same neu-
rons in NIFID (Supplementary Fig. 2B) in accordance with the FUS
and TAF15 results.
Absence of TAF15 and EWS pathology
in amyotrophic lateral sclerosis
with FUS mutations
Next, we analysed the pattern of TAF15 and EWS staining in six
ALS-FUS cases, which included four different FUS mutations. All
cases showed robust FUS pathology, particularly in the spinal cord
and motor cortex, with neuronal cytoplasmic inclusions (including
basophilic inclusions) as well as variable presence of glial inclusions
(Mackenzie et al., 2011b). Interestingly, and in striking contrast to
FTLD-FUS, neither TAF15 nor EWS immunohistochemistry demon-
strated any neuronal or glial inclusions in cortical, subcortical,
brainstem or spinal cord regions in any of the ALS-FUS cases
(Fig. 5). The absence of TAF15 and EWS immunoreactivity of
FUS-positive inclusions in ALS-FUS was further confirmed by
double-label immunofluorescence (Fig. 5G–L). Notably, cells with
FUS-immunoreactive inclusions retained their physiological nuclear
staining for TAF15 and EWS.
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TAF15 and EWS immunoreactivity
in neurological controls
The normal controls and the majority of neurological controls did
not reveal any TAF or EWS pathology (Table 2). Specifically, there
was no labelling of the characteristic inclusions in Alzheimer’s
disease, Lewy body disease, FTLD with tau pathology, ALS with
TDP-43 pathology or ALS due to SOD1 mutations. Inclusions in
FTLD with TDP-43 pathology were negative, with the exception
of one case that showed a small number of TAF15-positive cortical
neurites and EWS staining of a minority of inclusions in the hip-
pocampal dentate granule cells. Glial inclusions in multiple system
atrophy were negative for FUS and TAF15; however, one case
showed weak EWS labelling. Interestingly, intranuclear inclusions
in spinocerebellar ataxia and Huntington’s disease, previously
shown to be FUS positive (Doi et al., 2010; Woulfe et al.,
2010), were consistently labelled for EWS but not TAF15, while
the FUS-positive inclusions in neuronal intranuclear inclusion
body disease were negative for both. These findings for intranuc-
lear inclusions are noteworthy in suggesting that different combin-
ations of FET proteins are involved in inclusion formation in a
disease-specific fashion and that co-aggregation of all three FET
proteins is a specific feature of FTLD-FUS.
Biochemical analysis of TAF15 and EWS
in frontotemporal lobar degeneration
with FUS pathology
A change in the solubility of FUS protein has previously been
shown to be a consistent biochemical alteration in atypical
FTLD-U (Neumann et al., 2009b) and NIFID (Page et al., 2011).
To gain further insight into potential biochemical alterations of
TAF15 and EWS, proteins were sequentially extracted from
frozen brain tissue from FTLD-FUS, as well as normal and neuro-
logical controls, using a series of buffers containing detergents
and acids with an increasing ability to solubilize proteins.
Unfortunately, sufficient amounts of frozen tissue from ALS-FUS
cases were not available for analysis.
TAF15, EWS and FUS could be detected as major bands at the
expected molecular mass of 75, 90 and 73 kDa, respectively,
in the high salt (soluble proteins) and sodium dodecyl sulphate
(enriched for insoluble proteins) fractions from FTLD-FUS, as
well as controls (Fig. 6A). However, remarkable differences were
observed in the amount of the proteins in the distinct fractions in
FTLD-FUS compared with controls. In accordance with previous
findings, a clear shift of FUS towards the insoluble fraction was
Figure 1 TAF15 pathology in FTLD-FUS. TAF15 immunohistochemisty performed on sections of post-mortem brain tissue from normal
control (A), atypical FTLD-U (B–E), NIFID (F) and BIBD (G–J). Normal physiological staining pattern, consisting of strong immunoreactivity
of neuronal nuclei was seen in normal controls (A) and FTLD-FUS subjects (B). In atypical FTLD-U numerous round neuronal cytoplasmic
inclusions were seen in the dentate granule cells (B and C). Note the dramatically reduced nuclear staining in inclusion bearing cells (arrows
in C) compared with adjacent cells without inclusions (arrowhead in C). Neuronal intranuclear inclusions with vermiform (D) or ring-like
morphology (E) were a consistent finding in the dentate granule and pyramidal cells of the hippocampus in all subjects with atypical
FTLD-U. Numerous cytoplasmic inclusions with variable morphology ranging from round, crescentic, globular and tangle-like were present
in neurons in NIFID (F) and BIBD (G) as shown here in frontal cortex. All FTLD-FUS cases revealed at least rare inclusions in lower motor
neurons (H) as well as variable numbers of glial cytoplasmic inclusions in the white matter of affected brain regions (I, J). Scale bar: A, B, F
and G = 25 mm; C–E, I and J = 5 mm; H = 10mm.
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Figure 2 Co-localization of TAF15 and FUS in FTLD-FUS inclusions. Double-label immunofluorescence for FUS (red) and TAF15 (green),
with DAPI staining of nuclei in the merged images. (A) In atypical FTLD-U the vast majority of inclusions showed co-localization of
FUS and TAF15. (B) However, note that single neuronal intranuclear inclusions in atypical FTLD-U were not labelled for TAF15 (arrow)
while the cytoplasmic inclusion in the same cell shows co-localization (arrowhead). Consistent co-labelling for TAF15 was revealed for FUS
pathology in NIFID (C) and BIBD (D). Inclusions in the lower motor neurons (E, atypical FTLD-U case) and glial cytoplasmic inclusions
(F, BIBD case), also showed colocalization. Scale bar: A, C and D = 10 mm; B = 4mm; E and F = 6.5 mm.
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seen in all FTLD-FUS cases resulting in a significantly higher insol-
uble : soluble ratio (median 0.58, mean 2.51  3.54), compared
with controls (median 0.13, mean 0.17  0.17, P = 0.0038)
(Fig. 6B). A similar change in solubility was observed for TAF15
with a significantly higher insoluble : soluble ratio for FTLD-FUS
cases (median 2.47, mean 4.09  3.70) compared with controls
(median 0.50, mean 0.36  0.21, P = 0.0006). Notably, in some
FTLD-FUS cases the shift in solubility was even more pronounced
for TAF15 than that observed for FUS (e.g. atypical FTLD-U Case
14 and NIFID Case 2). For EWS, there was a similar tendency for
higher levels in the insoluble protein fraction in cases with
FTLD-FUS (median 1.55, mean 1.5  0.78) compared with con-
trols (median 0.80, mean ratio = 0.8  0.44); however, the differ-
ence did not reach significance.
Despite the change in solubility, there was no evidence of other
biochemical alterations of TAF15 and EWS, as indicated by abnor-
mal molecular weight species, using antibodies specific for differ-
ent TAF15 and EWS epitopes.
Genetic analysis of TAF15 and EWSR1
in frontotemporal lobar degeneration
with FUS pathology
Sequence analyses of EWSR1 and TAF15 did not identify any
novel coding variants in the eight FTLD-FUS cases with DNA
available, with the exception of a 24 base pair deletion in
TAF15 exon 15 in atypical FTLD-U Case 13 (c.1674_1697del),
predicted to delete eight amino acids (p.G559_Y566del). This par-
ticular deletion has not been reported previously; however, similar
deletions have been found in controls, suggesting it is likely a
benign polymorphism (Ticozzi et al., 2011). Novel non-coding
variants identified are summarized in Supplementary Table 3.
Characteristic features of human
FUS-opathies are recapitulated in
cultured cells
The strikingly different patterns of FET protein immunoreactivity in
the pathology of FTLD-FUS versus ALS-FUS, suggest different
mechanisms underlying inclusion body formation. To further ad-
dress this issue we investigated whether the absence of TAF15 and
EWS alterations seen in ALS-FUS would be recapitulated in cul-
tured cells expressing mutant FUS.
In accordance with previous results (Dormann et al., 2010),
HeLa cells expressing FUS with the p.P525L mutation (a mutation
present in two of our studied cases with ALS) showed a robust
increase of cytoplasmic FUS compared with cells expressing
wild-type FUS (Fig. 7A and Supplementary Fig. 3). Under stress
conditions of heat shock, cells expressing mutant FUS showed
recruitment of FUS into punctuate cytoplasmic structures,
Figure 3 EWS pathology in FTLD-FUS. EWS immunohistochemistry performed on sections of post-mortem brain tissue from normal
control (A), atypical FTLD-U (B–D, G), NIFID (E) and BIBD (F and H). Normal physiological staining pattern of nuclei and diffuse
cytoplasmic labelling (A). In atypical FTLD-U, round cytoplasmic and intranuclear inclusions were observed in the dentate granule cells
with variable labelling intensity (B). Higher magnification of cytoplasmic (C) and vermiform intranuclear inclusion (D) in atypical FTLD-U.
Numerous neuronal cytoplasmic inclusions with variable morphology including round, crescentic, globular and tangle-like showed strong
immunoreactivity in NIFID (E) and BIBD (F) as shown here in frontal cortex. Most cases with FTLD-FUS revealed at least rare inclusions
in lower motor neurons (G) as well as variable numbers of glial cytoplasmic inclusions in the white matter of affected brain regions (H).
Scale bar: A, B, E and F = 25 mm; C, D and H = 5mm; G = 10 mm.
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Figure 4 Co-localization of EWS and FUS in FTLD-FUS inclusions. Double-label immunofluorescence for FUS (red) and EWS (green), with
DAPI staining of nuclei in the merged images. In atypical FTLD-U, only a subset of FUS-positive neuronal cytoplasmic and intranuclear
inclusions were stained for EWS (A). In contrast, robust co-labelling for EWS and FUS was observed in most inclusions in NIFID (B) and
BIBD (C). Inclusions in the lower motor neurons (D, BIBD case) as well as glial cytoplasmic inclusions (E, BIBD case) also showed
co-localization. Scale bar: A–C = 10 mm; D = 6.5 mm; E = 4 mm.
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Figure 5 Absence of TAF15 and EWS pathology in ALS-FUS. Lower (A) and upper (D) motor neurons in all ALS-FUS cases contained at
least some cytoplasmic inclusions strongly labelled for FUS; however, no inclusions (including basophilic inclusions, arrows) were labelled
for TAF15 (B, lower motor neuron; E, upper motor neuron) or EWS (C, lower motor neuron; F, upper motor neuron). Note the regular
nuclear staining for both TAF15 (B and E) and EWS (C and F) in inclusion-bearing cells (arrows). The absence of TAF15 and EWS
pathology in ALS-FUS was confirmed by double-label immunofluorescence that showed robust FUS-immunoreactivity of round and
tangle-like neuronal inclusions in the spinal cord (red, G–J) that were not labelled for TAF15 (green in G and I) or EWS (green in H and J).
In addition, FUS-positive glial cytoplasmic inclusions present in a subset of cases (red, K and L, basal ganglia) showed no co-localization for
TAF15 (green, K) or EWS (green, L). Scale bar in A: A–C = 10 mm; D–F = 22 mm. Scale bar in G: G–J = 10 mm; K and L = 30 mm.
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corresponding to stress granules. In contrast, these same condi-
tions resulted in no changes in the subcellular distribution of en-
dogenous TAF15 or EWS. Specifically, both proteins remained
almost exclusively within the nucleus and there was no recruit-
ment of TAF15 or EWS into FUS-positive stress granules. In
this way, cells expressing an ALS-associated FUS mutation
recapitulate our findings in human ALS-FUS, demonstrating the
absence of other FET protein members in cytoplasmic FUS
inclusions.
To investigate whether the accumulation of all FET proteins in
FTLD-FUS might reflect a more general problem of Transportin-
mediated nuclear import, we studied the effect on TAF15 and
EWS by transfecting HeLa cells with a Transportin-specific com-
petitive inhibitor peptide (M9M) fused to green fluorescent protein
(Fig. 7B). Similar to what has been shown previously for FUS
(Dormann et al., 2010), a striking redistribution of endogenous
TAF15 and EWS proteins to the cytoplasm was observed, that
was associated with the formation of stress granules with
co-localization of all FET proteins. Notably, recruitment of FUS
and TAF15 into stress granules in this system seemed to be
more efficient compared with EWS, based on staining intensities
of stress granules, recapitulating the differences we observed in
the staining intensities of inclusions for FET proteins in atypical
FTLD-U. Furthermore, the most obvious reduction of normal
nuclear protein levels was found for TAF15, similar to the dramatic
decrease in nuclear staining intensity in inclusion bearing cells in
FTLD-FUS. Thus, inhibition of Transportin-mediated nuclear import
in cultured cells mimics characteristic alterations of FET proteins
found in human FTLD-FUS.
Discussion
FUS accumulates in the pathological cellular inclusions that char-
acterize all cases of ALS with FUS mutations and a variety of FTLD
subtypes, collectively referred to as FTLD-FUS (Kwiatkowski et al.,
2009; Munoz et al., 2009; Neumann et al., 2009a, b; Vance
et al., 2009; Mackenzie et al., 2010b). Our knowledge of the
underlying mechanisms leading to FUS accumulation and
FUS-mediated cell death is still limited. So far, most insights
come from studies analysing the functional consequences of FUS
mutations. As demonstrated in cell culture experiments, pathogen-
ic FUS mutations interfere with the Transportin-mediated nuclear
import, leading to increased levels of cytoplasmic FUS where it is
recruited into stress granules upon stress conditions (Dormann
et al., 2010; Ito et al., 2011; Kino et al., 2011). Since stress gran-
ule markers have been found in FUS-positive inclusions in
FTLD-FUS and ALS-FUS, it has been suggested that stress granules
might be the precursors of pathological FUS-inclusions (Dormann
et al., 2010; Dormann and Haass, 2011).
Although there is some clinical and pathological overlap
between ALS-FUS and FTLD-FUS, the presence of significant
differences in the phenotypes and the morphological patterns of
FUS pathology (Mackenzie et al., 2011b) and the fact that no
FTLD-FUS case has yet been associated with a FUS mutation
(Neumann et al., 2009a, b; Rohrer et al., 2010; Urwin et al.,
2010; Snowden et al., 2011), raise questions as to whether
these conditions represent a clinicopathological spectrum of dis-
eases with a shared pathomechanism or whether the pathogenic
pathways triggered by FUS mutations may be different from those
involved in FTLD-FUS.
In the present study, we performed a detailed analysis of the
role of the FUS homologues TAF15 and EWS in the spectrum of
FUS-opathies and identified remarkable differences in the protein
composition of inclusions between FTLD-FUS and ALS-FUS. These
findings strongly support the idea that the pathological processes
underlying cell death in ALS-FUS might be different from those in
FTLD-FUS.
None of the ALS-FUS cases investigated, including six cases with
four different FUS mutations, showed any alteration in the sub-
cellular distribution of TAF15 or EWS and no evidence of
co-accumulation of these proteins in the FUS-positive pathological
inclusions. Importantly, we confirmed retention of the normal
physiological staining pattern and the absence of TAF15 and
EWS co-localization in the cytoplasmic FUS pathology (i.e. stress
granules) that develops in cultured cells expressing ALS-associated
FUS mutations (Dormann et al., 2010). Thus, cytoplasmic
accumulation of FUS per se does not trigger an alteration in the
subcellular distribution of its homologues and does not lead to
sequestration of TAF15 and EWS into FUS inclusions as a second-
ary phenomenon. This strongly implies that the pathological pro-
cesses in ALS-FUS are restricted to dysfunctions of FUS. Since the
ALS-FUS cases we studied do not cover the entire spectrum of
reported FUS mutations, we cannot exclude the possibility that
other FUS mutations, particularly those reported in exons 3, 5 or
6 (Mackenzie et al., 2010a) might be associated with TAF15 and/
or EWS pathology. However, since our analysis did include two
Table 2 Immunoreactivity for FET proteins in other
neurodegenerative diseases
Diagnosis FUS TAF15 EWS
AD 0/4 0/4 0/4
FTLD-TDP 0/17 1/17a 1/17a
FTLD with CHMP2B 0/2 0/2 0/2
FTLD-tau 0/8 0/8 0/8
ALS-TDP 0/8 0/8 0/8
ALS with SOD1 0/2 0/2 0/2
MSA 0/2 0/2 1/2b
LBD 0/2 0/2 0/2
SCA 3/3 0/3 3/3
HD 2/2 0/2 2/2
NIIBD 1/1 0/1 0/1
a One FTLD-TDP subtype 2 case [according to (Mackenzie et al., 2006)] with
semantic dementia showed moderated EWS-immunoreactivity in a subset of
neuronal cytoplasmic inclusions in the dentate gyrus and TAF15-immunoreactivity
in a small proportion of long neurites.
b One case showed EWS-immunoreactivity in a small proportion of glial
cytoplasmic inclusions.
AD = Alzheimer’s disease; ALS-TDP, amyotrophic lateral sclerosis with TDP-43
pathology; ALS with SOD1 = amyotrophic lateral sclerosis due to mutations in
SOD1 gene; FTLD-TDP = frontotemporal lobar degeneration with TDP-43 path-
ology; FTLD-tau, frontotemporal lobar degeneration with tau pathology; FTLD
with CHMP2B = frontotemporal lobar degeneration with mutations in CHMP2B
gene; HD = Huntington’s disease; LBD = Lewy body disease; MSA = multiple
system atrophy; NIIBD = neuronal intranuclear inclusion body disease;
SCA = spinocerebellar ataxia.
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cases with the most common FUS mutation (p.R521C), this is
unlikely to be a frequent finding.
In sharp contrast to ALS-FUS, abnormal co-accumulation of all
three FET proteins into pathological inclusions was a consistent
and specific feature of all subtypes of FTLD-FUS. This finding fur-
ther extends the similarities between the various subtypes of
FTLD-FUS, thereby strongly supporting the idea, that atypical
FTLD-U, NIFID and BIBD are closely related disease entities
Figure 6 Biochemical analysis of FET proteins in FTLD-FUS. (A) Proteins were sequentially extracted from frontal cortex of atypical
FTLD-U, NIFID, BIBD, normal as well as neurological controls. High salt (Lane 1), Triton-X-100 (Lane 2), radioimmunoprecipitation assay
buffer (Lane 3), 2% sodium dodecyl sulphate (Lane 4) and formic acid (Lane 5) protein fractions were separated by sodium dodecyl
sulphate–polyacrylamide gel electrophoresis and immunoblotted with anti-TAF15 (TAF15-309A), EWS (G5) and FUS (FUS-302A). All
proteins were present in the soluble high salt fraction and sodium dodecyl sulphate fraction in each case as one major band at the expected
molecular size for the full-length proteins. However, the amount of TAF15 and FUS in the sodium dodecyl sulphate fraction was much
higher in FTLD-FUS compared with controls, while the shift towards the sodium dodecyl sulphate fraction was less obvious for EWS.
(B) Densitometric quantification of band intensities of FUS, TAF15 and EWS in the soluble (high salt) and insoluble (sodium dodecyl
sulphate) fraction was performed. Calculated insoluble/soluble ratios for each protein in the FTLD-FUS (n = 7) and control group (n = 11,
including four normal controls, five FTLD with TDP-43 pathology and two cases with Alzheimer’s disease) are shown as box plot showing
the range of values, with the box being subdivided by the median into the 25th and 75th percentiles. Filled rhombus represents the mean;
circles represent outliers. aFTLD-U = atypical FTLD-U.
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Figure 7 Analysis of FET proteins in cell culture systems. (A) Cytoplasmically mislocalized mutant FUS does not sequester TAF15 or EWS
into stress granules upon heat shock. HeLa cells transiently transfected with haemagglutinin-tagged human FUS with the P525L mutation
(HA-FUS-P525L) were left untreated (37C, top) or subjected to heat shock (1 h at 44C, bottom) 24 h after transfection. Cells were
stained with antibodies against haemagglutinin (green) and EWS (red) or TAF15 (red) and analysed by confocal microscopy. Under control
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(continued)
(Mackenzie et al., 2011a). However, our results also suggest some
important differences among distinct FET family members in the
different FTLD-FUS subtypes. While antibodies against TAF15 ro-
bustly labelled virtually all FUS pathology in atypical FTLD-U,
NIFID and BIBD, subtle disease-specific differences were observed
for EWS. Only a proportion of inclusions in atypical FTLD-U cases
labelled for EWS and the staining intensity was often weak. In
contrast, inclusions in NIFID and BIBD were more consistently
and robustly labelled for EWS. Because the quality of immunos-
taining obtained with the commercial EWS antibodies employed
was not felt to be optimal in all sections, we are cautious in in-
terpreting these results. However, they raise the possibility of
subtle differences in the pathogenic pathways involved in the dif-
ferent FTLD-FUS subtypes, that may underlie the distinct clinico-
pathological phenotypes previously described (Mackenzie et al.,
2011a).
Another difference in the pattern of immunostaining among
the FET proteins in FTLD-FUS is worth noting for its potential
functional significance. Whereas inclusion bearing cells often
demonstrated at least partial retention of nuclear FUS and EWS
localization, a dramatic and consistent reduction of physiological
nuclear staining was observed for TAF15, suggesting a possible
loss-of-function mechanism.
The mechanisms leading to the accumulation of all FET proteins
in FTLD-FUS remain unclear. The results in human ALS-FUS and
in cultured cells expressing mutant FUS indicates that other FET
proteins are not secondarily entrapped within FUS inclusions.
An alternate mechanism is suggested by our cell culture data in
which inhibition of Transportin-mediated nuclear import resulted
in recruitment and co-localization of all FET proteins into stress
granules. This favours a scenario in which a broader nuclear
import defect in FTLD-FUS leads to increased cytoplasmic levels
of all FET proteins (and possibly other proteins), which then pre-
disposes to their abnormal accumulation. Although the underlying
defect in nuclear import could reflect a direct dysfunction of the
Transportin import machinery, preliminary studies in which we
found no alterations in the subcellular distribution of other
Transportin cargos, such as hnRNPA1, makes this mechanism
more unlikely. Alternatively, altered post-translational modifica-
tions of FET proteins, such as phosphorylation or arginine methy-
lation, might affect their subcellular localization and nuclear import
in FTLD-FUS (Tan and Manley, 2009; Kovar, 2011). While
biochemical analysis has so far revealed only a relative change in
solubility for FET proteins (Neumann et al., 2009b and this study),
the presence of potential disease-associated post-translational
modifications as well as alterations of the transportin machinery
requires further studies.
Our findings in FTLD-FUS add TAF15 and EWS to the growing
list of DNA/RNA binding proteins involved in neurodegenerative
diseases. Despite the fact that we have not detected any patho-
genic mutations in TAF15 and EWSR1 in our FTLD-FUS cases,
both genes are considered promising candidates for genetic
screens in FTLD and ALS and a very recent report has described
coding variants in TAF15 in ALS, although their pathogenicity re-
mains to be confirmed (Ticozzi et al., 2011).
In summary, this study demonstrates the co-accumulation of all
members of the FET protein family in the characteristic inclusions
as specific feature of FTLD-FUS but not of ALS-FUS, thus allowing
a clear separation between genetic and non-genetic forms of
FUS-opathies by neuropathological features. More importantly,
these findings imply that different pathomechanisms underlie in-
clusion body formation and cell death in ALS-FUS versus
FTLD-FUS. Our data indicate that neurodegeneration associated
with FUS mutations is probably the result of a restricted dysfunc-
tion of FUS, whereas a more complex dysregulation of all FET
family members seems to be involved in FTLD-FUS pathogenesis.
While the relative roles of the different FET proteins in the disease
pathogenesis of FTLD-FUS remain to be determined in future stu-
dies, our data suggest that the conditions currently subsumed
within the FTLD-FUS molecular subgroup might be more appro-
priately designated as FTLD-FET, in accordance with the recently
proposed system of FTLD nomenclature (Mackenzie et al., 2009).
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with a nuclear depletion of these proteins. Scale bar = 20 mm.
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